PNC Financial Services Group
NRSN icon

PNC Financial Services Group’s NeuroSense Therapeutics NRSN Stock Holding History

PNC Financial Services Group’s Portfolio NRSN Stock Details NRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.69K Hold
1,058
– – ﹤0.01% 4532
2026
Q2 		$15.2K Hold
1,058
– – ﹤0.01% 3902
2026
Q1 		$16K Buy
+1,058
New +$18.9K ﹤0.01% 3784

Other funds holding NRSN

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

PNC Financial Services Group's NRSN Position: Q3 2026 in Review

PNC Financial Services Group held its NeuroSense Therapeutics (NRSN) position steady in Q3 2026 at 1,058 shares worth $4.69K. The position accounts for ﹤0.01% of the portfolio, ranked #4532.

PNC Financial Services Group first reported a position in NRSN in Q1 2026 and has held it in 3 quarters since. The position peaked at $16K in Q1 2026. 4 funds tracked by Wall St. Rank hold NRSN as of Q3 2026.

  • PNC Financial Services Group held 1,058 shares of NeuroSense Therapeutics worth $4.69K as of Q3 2026.
  • PNC Financial Services Group left its NeuroSense Therapeutics share count unchanged in Q3 2026.
  • NeuroSense Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #4532 holding.
  • PNC Financial Services Group first reported a position in NeuroSense Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • PNC Financial Services Group's NeuroSense Therapeutics position peaked at $16K in Q1 2026.
  • 4 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q3 2026.

Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.